Confidential — authorized recipients only
We build the authentication and economic-deterrence layer that makes counterfeiting unprofitable. We start in pharmaceuticals with MedAuth, then extend the same core system — sector by sector — wherever a fake can reach a person.
The same handful of entry vectors reappear whether the product is a vial of insulin, a handbag, a brake pad, or a bottle of wine. Different industries call them different names — the mechanics are the same.
Genuine product leaves the authorized network — returns, excess inventory, theft — and re-enters through resellers who aren't checked as carefully. Counterfeiters slip fakes into the same loosely-controlled channel.
Real lot numbers, real-looking packaging, cloned serials. Built to pass a visual check and a basic "does this serial exist" lookup — the exact test most track-and-trace systems stop at.
Marketplace listings, social-commerce storefronts, and messaging-app sellers move product directly to a buyer with no authorized dispenser or retailer in the middle at all.
Someone with legitimate access to the line prints more units than were ever registered, and the surplus quietly leaves through the front door with everything else.
Genuine outer packaging, genuine seals — the contents inside are swapped somewhere between the factory and the point of sale, where nobody is opening the box to check.
Whenever legitimate supply is tight, buyers get less careful about where they source from — and that's exactly when counterfeit volume spikes.
These same entry vectors appear across pharmaceuticals, medical devices, luxury goods, wine & spirits, automotive parts, electronics, and agrochemicals. That is why one authentication architecture — a living token, an enforced lifecycle, and economic self-defeat — can be built once and extended sector by sector, instead of being reinvented for every industry.
Figures below are drawn from publicly reported estimates by OECD/EUIPO, the World Health Organization, the U.S. CDC, and manufacturer security disclosures. Ranges exist because methodologies differ — every figure is attributed so it can be checked against the original source.
All industries. Estimated annual value of international trade in counterfeit and pirated goods — up to 3.3% of world trade.
Electronics. Estimated annual global cost of counterfeit electronic components and finished devices to manufacturers and buyers.
Automotive. Estimated annual global value of counterfeit auto parts — brakes, airbags, and sensors sold as OEM-grade.
Food & agriculture. Estimated annual global cost of food fraud and adulteration to the food industry.
Pharmaceuticals. Medical products circulating in low- and middle-income countries estimated to be substandard or falsified.
Pharmaceuticals. Approximate annual U.S. overdose deaths in recent years involving fentanyl — much of it consumed unknowingly, in counterfeit pills.
These are third-party figures cited for directional scale across sectors, not internally verified numbers — several are multi-year or methodology-dependent estimates, and pharma-specific figures shift year to year as fentanyl-supply patterns change. Before using any of these in an investor deck or regulatory filing, pull the current figure directly from the cited source.
Every version of this system — MedAuth included — is built on the same idea: give each physical unit one live, cryptographic identity, and enforce its lifecycle instead of merely recording it. The system is additive. It sits on top of the track-and-trace or serialization infrastructure already in place in each sector — no rip-and-replace required.
At the point of manufacture, every dispensable or sellable unit is issued a single cryptographic token — not merely a printed serial number, but a live identity that carries state.
The token moves through a defined sequence of custody states. Each legitimate handoff advances it. Presenting it out of sequence, twice, or at the wrong location is caught immediately — not reconciled later.
The first legitimate scan at each gate consumes that step. Any later presentation of the same token — anywhere, by anyone — is flagged instantly as a duplicate, rather than discovered on a later audit.
At the point of final sale or dispensing, the token closes permanently. There is no valid way to present it again — closing the reuse loophole most track-and-trace systems leave open by design.
Cloning a token only works once. The moment both the clone and the genuine unit are presented, both are flagged. Every successful counterfeit sale therefore destroys the value of a genuine unit the counterfeiter had to obtain in the first place — turning scale into a liability.
An independent image match against the manufacturer's reference catches genuine packaging wrapped around the wrong contents. This layer is used where packaging and contents can meaningfully diverge (pharma, cosmetics, spirits, and similar categories). It is not relied on for categories such as electronic components or auto parts, where the token lifecycle and economic self-defeat carry the greater share of protection.
Pharmaceuticals sets the bar — patient safety, DSCSA-level regulatory scrutiny, and a full physical supply chain. Every sector after that reuses more of the architecture than it rebuilds.
MedAuth pilot live with one to two manufacturers, Consumer App and Pharmacy App in the field, and the Online Intelligence Layer monitoring official brand-protection channels for the same molecules.
Medical devices reuse the same regulatory posture and safety stakes; dietary supplements and OTC products reuse the consumer app and online-monitoring layer where counterfeiting is often worse due to lighter regulation.
Luxury goods, wine & spirits, and prestige beauty share the same online marketplace exposure as pharma's illegal-channel problem, plus consumers already primed to expect authentication at the point of purchase.
Automotive safety parts and electronics extend the physical chain-of-custody model into B2B-heavy distribution; agrochemicals bring the same danger profile as pharma to a completely different buyer — the farmer.
MedAuth is designed as an additive layer. It consumes existing DSCSA / EPCIS 2.0 events (real-time or batch) and sits on top of the systems manufacturers already run — no rip-and-replace required.
The first live pilot covers both channels of the pharmacy trade — brick-and-mortar and online — the highest-stakes, most tightly regulated environment we work in, and the proving ground for every sector that follows it.